Ieva Jasiukenaite will take on an important role in defining communication strategy for ZERION and ensure high quality content and news updates for our followers on the website and social media platforms. Ieva joins ZERION with 6+ years of experience working with strategic communication and digital marketing as well as graphical design.
Camila Belavi will support the formulation team in the pre-clinical experimental activities of Dispersome® formulations for ZERION’s drug development programs. Camila joins ZERION with 3+ years of industry experience working with pharmaceutical formulation development including controlled release drug projects with poorly soluble drug compounds and biopolymers.
We are excited to have Ieva and Camila join our team and take part in our journey to commercialize our Dispersome® medicinal products.
AUGUST 29, 2022 (COPENHAGEN, Denmark). The Danish pharmaceutical company Zerion Pharma A/S (ZERION) and the Spanish pharmaceutical group Insud Pharma, SL today are announcing their collaboration to develop
AUGUST 23, 2022 (COPENHAGEN, Denmark). Zerion Pharma A/S (ZERION) and Hovione today announced an extension of their collaboration on ZERION’s Dispersome® technology into the nutraceutical/dietary supplements field.
February 23, 2022 (COPENHAGEN, Denmark). Zerion Pharma A/S (“ZERION”) announces today that it has executed a long-term agreement with Arla Foods Ingredients covering the supply of its Lacprodan® BLG-100 for use as